Development of monolithic matrix type transdermal patches containing cinnarizine
Physical characterization and permeation studies
DOI:
https://doi.org/10.1590/s2175-97902022e19859Palavras-chave:
Cinnarizine, Penetration enhancers, Topical application, Transdermal delivery, Transdermal patchesResumo
To overcome the problems associated with bioavailability and systemic side effects of the drug by oral administration, monolithic matrix type transdermal patches containing cinnarizine (CNZ) were developed. For this purpose, films based on hydroxypropyl methylcellulose and polyvinylpyrrolidone as matrix-forming polymers were designed. Physical characteristics of transdermal films and drug-excipient compatibility were investigated. Factors affecting in vitro drug release and ex vivo skin penetration and permeation of the drug were studied. It was confirmed that films displayed sufficient flexibility and mechanical strength for application onto the skin for a long time period. Ex vivo penetration experiments gave satisfactory results for transdermal drug delivery through rat skin. The parameters determining good skin penetration were also evaluated. The highest drug permeation rate was obtained with incorporation of Transcutol® (0.102 mg/cm2/h) into the base CNZ formulation, followed by propylene glycol (0.063 mg/cm2/h), menthol (0.045 mg/cm2/h), and glycerin (0.021 mg/cm2/h) as penetration enhancers (p < 0.05). As a result, the developed transdermal patches of CNZ may introduce an alternative treatment for various conditions and diseases such as idiopathic urticarial vasculitis, Ménière’s disease, motion sickness, nausea, and vertigo. Thus, the risk of systemic side effects caused by the drug can be reduced or eliminated.
Downloads
Referências
(4) Harmonization: <905> Uniformity of Dosage Forms. [citad 2016 Nov 21]. Available from: Available from: https://www.usp.org/sites/default/files/usp/document/harmonization/gen-method/q0304_pf_30_4_2004.pdf
» https://www.usp.org/sites/default/files/usp/document/harmonization/gen-method/q0304_pf_30_4_2004.pdf
Akram MR, Ahmad M, Abrar A, Sarfraz RM, Mahmood A. Formulation design and development of matrix diffusion controlled transdermal drug delivery of glimepiride. Drug Des Devel Ther. 2018;12:349-64.
Alsaqr A, Rasoully M, Musteata FM. Investigating transdermal delivery of vitamin D3. AAPS PharmSciTech. 2015;16(4):963-72.
Ceschel GC, Bergamante V, Maffei P, Lombardi Borgia S, Calabrese V, Biserni S, et al. Solubility and transdermal permeation properties of a dehydroepiandrosterone cyclodextrin complex from hydrophilic and lipophilic vehicles. Drug Deliv. 2005;12(5):275-80.
Cho CW, Kim DB, Cho HW, Shin SC. Enhanced controlled transdermal delivery of ambroxol from the EVA matrix. Indian J Pharm Sci. 2012;74(2):127-32.
Costa P, Sousa Lobo JM. Evaluation of mathematical models describing drug release from estradiol transdermal systems. Drug Dev Ind Pharm. 2003;29(1):89-97.
Damgalı Ş. Preparation and characterization of cinnarizine topical dosage forms. [Doctoral dissertation]. Istanbul: Istanbul University; 2017.
Djelilovic-Vranic J, Alajbegovic A, Tiric-Campara M, Volic A, Sarajlic Z, Osmanagic E, et al. Betahistine or cinnarizine for treatment of Meniere's disease. Med Arch. 2012;66(6):396-8.
El Nabarawi MA, Shaker D, Attia DA, Hamed SA. In vitro skin permeation and biological evaluation of lornoxicam monolithic transdermal patches. Int J Pharm Pharm Sci. 2013;5(2):242-8.
European Chemical Bureau, Dir 92/69/EEC. [citad 1992 Jul 31]. Available from: Available from: https://publications.europa.eu/en/publication-detail/-/publication/17c85561-c516-4dff-aed6-e908140f9bb3
Fahmy AM, El-Setouhy DA, Ibrahim AB, Habib BA, Tayel SA, Bayoumi NA. Penetration enhancer-containing spanlastics (PECSs) for transdermal delivery of haloperidol: in vitro characterization, ex vivo permeation and in vivo biodistribution studies. Drug Deliv . 2018;25(1):12-22.
Funke AP, Schiller R, Motzkus HW, Günther C, Müller RH, Lipp R. Transdermal delivery of highly lipophilic drugs: in vitro fluxes of antiestrogens, permeation enhancers and solvents from liquid formulations. Pharm Res. 2002;19(5):661-8.
Ganem-Quintanar A, Lafforgue C, Falson-Rieg F, Buri P. Evaluation of the transepidermal permeation of diethylene glycol monoethyl ether and skin water loss. Int J Pharm. 1997;147(2):165-71.
Ham AS, Lustig W, Yang L, Boczar A, Buckheit KW, Buckheit Jr RW. In vitro and ex vivo evaluations on transdermal delivery of the HIV inhibitor IQP-0410. PLoS One. 2013;8(9):e75306.
Haq A, Michniak-Kohn B. Effects of solvents and penetration enhancers on transdermal delivery of thymoquinone: permeability and skin deposition study. Drug Deliv . 2018;25(1):1943-9.
Haress NG. Cinnarizine: Comprehensive profile. Profiles Drug Subst Excip Relat Methodol. 2015;40:1-41.
Higuchi T. Mechanism of sustained action medication. Theoretical analysis of rate of release of solid drugs dispersed in solid matrices. J Pharm Sci. 1963;52:1145-9.
Holmes B, Brogden RN, Heel RC, Speight TM, Avery GS. Flunarizine. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use. Drugs. 1984;27(1):6-44.
Houston DMJ, Bugert J, Denyer SP, Heard CM. Anti-inflammatory activity of Punica granatum L. (Pomegranate) rind extracts applied topically to ex vivo skin. Eur J Pharm Biopharm. 2017;112:30-7.
ICH Harmonised Tripartite Guideline: Validation of Analytical Procedures: Text and Methodology Q2 (R1). Harmonization Co, Editor; [citad 2005 Nov]. Available from: Available from: https://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q2_R1/Step4/Q2_R1__Guideline.pdf
Jatav VS, Saggu JS, Sharma AK, Sharma A, Jat RK. Design, development and permeation studies of nebivolol hydrochloride from novel matrix type transdermal patches. Adv Biomed Res. 2013;2:62.
Kalava BH, Demirel M, Yazan Y. Physicochemical characterization and dissolution properties of cinnarizine solid dispersions. Turkish J Pharm Sci . 2005;2(2):51-62.
Korsmeyer RW, Gurny R, Doelker E, Buri P, Peppas NA. Mechanisms of solute release from porous hydrophilic polymers. Int J Pharm . 1983;15(1):25-35.
Kunta JR, Goskonda VR, Brotherton HO, Khan MA, Reddy IK. Effect of menthol and related terpenes on the percutaneous absorption of propranolol across excised hairless mouse skin. J Pharm Sci . 1997;86(12):1369-73.
Liu X, Chen T, Liu X, Chen Y, Wang L. Penetration effect of ostrich oil as a promising vehicle on transdermal delivery of sinomenine. J Oleo Sci. 2013;62(9):657-64.
Loh GOK, Tan YT, Peh KK. Effect of HPMC concentration on β-cyclodextrin solubilization of norfloxacin. Carbohydr Polym. 2014;101:505-10.
Martinez MA, Carril-Aviles MM, Sagrado S, Villanueva-Camanas RM, Medina-Hernandez MJ. Characterization of antihistamine-human serum protein interactions by capillary electrophoresis. J Chromatogr A. 2007;1147(2):261-9.
Mohamed MA, Attia AK. Thermal behavior and decomposition kinetics of cinnarizine under isothermal and non-isothermal conditions. J Therm Anal Calorim. 2017;127(2):1751-56.
Nicoli S, Zani F, Bilzi S, Bettini R, Santi P. Association of nicotinamide with parabens: Effect on solubility, partition and transdermal permeation. Eur J Pharm Biopharm . 2008;69(2):613-21.
Ogata H, Aoyagi N, Kaniwa N, Ejima A, Sekine N, Kitamura M, et al. Gastric acidity dependent bioavailability of cinnarizine from two commercial capsules in healthy volunteers. Int J Pharm . 1986;29(1-2):113-20.
Osborne DW, Musakhanian J. Skin penetration and permeation properties of Transcutol® - Neat or diluted mixtures. AAPS PharmSciTech . 2018;19(8):3512-33.
Paudel KS, Milewski M, Swadley CL, Brogden NK, Ghosh P, Stinchcomb AL. Challenges and opportunities in dermal/transdermal delivery. Ther Deliv. 2010;1(1):109-31.
Pond SM, Tozer TN. First-pass elimination. Basic concepts and clinical consequences. Clin Pharmacokinet. 1984;9(1):1-25.
Powell-Dunford N, Bushby A. Management of sea sickness in susceptible flight crews. Mil Med. 2017;182(11):e1846-50.
Rowe RC, Sheskey PJ, Owen SC. Handbook of Pharmaceutical Excipients. 6th ed. New York: Pharmaceutical Press; 2009. p. 624-626.
Shi S, Chen H, Cui Y, Tang X. Formulation, stability and degradation kinetics of intravenous cinnarizine lipid emulsion. Int J Pharm . 2009;373(1-2):147-55.
Sloan KB, Koch SA, Siver KG, Flowers FP. Use of solubility parameters of drug and vehicle to predict flux through skin. J Invest Dermatol. 1986;87(2):244-52.
Sweetman SC. Martindale: The Complete Drug Reference. 36th ed. New York: Pharmaceutical Press ; 2009. p. 573-574.
Thakur G, Singh A, Singh I. Formulation and evaluation of transdermal composite films of chitosan-montmorillonite for the delivery of curcumin. Int J Pharm Investig. 2016;6(1):23-31.
Thomas S, Chong YN, Chaw CS. Preparation and characterization of enteric microparticles by coacervation. Drug Dev Ind Pharm . 2013;39(7):1142-51.
Tosoni C, Lodi-Rizzini F, Cinquini M, Pasolini G, Venturini M, Sinico RA, et al. A reassessment of diagnostic criteria and treatment of idiopathic urticarial vasculitis: a retrospective study of 47 patients. Clin Exp Dermatol. 2009;34(2):166-70.
Üner M, Karaman EF. Preliminary studies on solid lipid microparticles of loratadine for the treatment of allergic reactions via the nasal route. Trop J Pharm Res . 2013;12(3):287-93.
Wiechers JW. The barrier function of the skin in relation to percutaneous absorption of drugs. Pharm Weekbl Sci. 1989;11(6):185-98.
Williams AC, Barry BW. Penetration enhancers. Adv Drug Deliv Rev. 2004;56(5):603-18.
Yeo LK, Olusanya TOB, Chaw CS, Elkordy AA. Brief effect of a small hydrophobic drug (cinnarizine) on the physicochemical characterisation of niosomes produced by thin-film hydration and microfluidic methods. Pharmaceutics. 2018;10(4):E185.
Yi QF, Yan J, Tang SY, Huang H, Kang LY. Effect of borneol on the transdermal permeation of drugs with differing lipophilicity and molecular organization of stratum corneum lipids. Drug Dev Ind Pharm . 2016;42(7):1086-93.
Downloads
Publicado
Edição
Seção
Licença
Copyright (c) 2022 Brazilian Journal of Pharmaceutical Sciences
Este trabalho está licenciado sob uma licença Creative Commons Attribution 4.0 International License.
All content of the journal, except where identified, is licensed under a Creative Commons attribution-type BY.
The on line journal has open and free access.
Como Citar
Dados de financiamento
-
Istanbul Üniversitesi
Números do Financiamento 40188 -
Türkiye Bilimsel ve Teknolojik Araştırma Kurumu
Números do Financiamento TEYDEB 1649B031305845
